An accomplished biotechnology and healthcare executive, having held various director and management roles. A proven track record in securing licensing deals, M&A transactions and early stage product development. Throughout career have developed valuable business relationships and innovative strategies, resulting in successful deals and partnerships in North America, Europe and several emerging economies and nations including Russia, India and China. Recognised in 2009 one of the Top 100 Women in Seattle Technology and a regular speaker at industry events, regarded as an expert in entrepreneurial approaches to business and passionate about the role that diversity can play in a company's success. Since joining Allozyne in 2007, have led and transformed the company as President and CEO. Since its formation, Allozyne has raised $50M and is supported by a top tier venture investor syndicate including MPM Capital and Arch Ventures. Through leadership and management of that funding has been able to rapidly progress the platforms to practice and build a significant clinical stage pipeline with distinct product opportunities that reflect the breadth of the platform and maintain the company’s focus on addressing areas of unmet medical need in autoimmune disease and oncology.